Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

Figures & data

Video Abstract

Infographic: A PDF version of this infographic is available as supplemental material.

Figure 1. Time on treatment with sequential afatinib and osimertinib.

(A) All patients; (B) Asian patients; and (C) patients with Del19-positive tumors.

Table 1. Time on treatment and overall survival across patient subgroups.

Baseline demographic/disease characteristic	Median time on treatment (90% CI), months	Median OS (90% CI), months
Overall population	27.7 (26.7–29.9)	37.6 (35.5–41.3)
Ethnicity
Non-Asian (n = 137)	27.6 (26.3–29.3)	36.7 (34.4–41.6)
Asian (n = 50)	37.1 (28.1–40.3)	44.8 (37.0–57.8)
Age at start of afatinib (years)
<65 years (n = 132)	28.7 (26.8–30.0)	37.6 (35.7–41.3)
≥65 years (n = 71)	27.3 (20.4–31.3)	36.9 (33.0–44.8)
EGFR mutation at start of afatinib
Del19 (n = 149)	30.0 (27.6–31.9)	41.6 (36.9–45.0)
L858R (n = 53)	19.1 (16.8–26.3)	33.0 (29.8–37.0)
Presence of brain metastases
Yes (n = 21)	22.2 (16.8–29.9)	31.0 (19.5–45.0)
No (n = 182)	28.1 (27.0–30.3)	38.0 (35.9–41.6)
ECOG PS
0/1 (n = 152)	30.0 (28.1–31.7)	41.0 (37.6–45.0)
≥2 (n = 31)	22.2 (16.0–26.5)	32.0 (24.5–34.5)

ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR: Epidermal growth factor receptor; OS: Overall survival.

Figure 2. Overall survival in patients treated with sequential afatinib and osimertinib.

(A) All patients; (B) Asian patients; and (C) patients with Del19-positive tumors.

OS: Overall survival.